Cancer Immunotherapy Market

March 2018 | | ID: CBBDB808F71EN
Progressive Markets (owned by Antviews Global)

Abstracts

CANCER IMMUNOTHERAPY MARKET - OVERALL INDUSTRY ANALYSIS

The global cancer immunotherapy market was valued at $57,256.2 million in 2017 and is expected to reach $166,714.5 million by 2025, registering a CAGR of 14.42% during the period, 2018-2025. Cancer is a concerning health issue globally and patients succumb to the disease every single day. Among the various modes of treatment, using the immune system to treat cancer or cancer immunotherapy has gained widespread importance in the recent years. Cancer immunotherapy deals with the interaction between cancer cells and the immune system. It harnesses certain components of the immune system to fight cancer. The treatment can be done in several ways. Some of them involve stimulating the body’s immune system to work harder to attack cancer cells while some others involve providing the immune system with man-made immune system proteins to fight cancer cells. The various types of immunotherapy used to treat cancer include monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and other immunotherapies.

CANCER IMMUNOTHERAPY MARKET DRIVERS AND RESTRAINTS

The cancer immunotherapy market is a fiercely competitive one with several big players operating in the field. The report says that the rise in funding from various government and private organizations for carrying out R&D activities for cancer immunotherapy, growing incidence of cancer globally, rise in approvals for the clinical trials and the growing acceptance of cancer immunotherapy are driving the demand of the industry. On the other hand, the high cost associated with cancer immunotherapy restrains the industry growth.

KEY MARKET SEGMENTATION

Cancer Immunotherapy Market Segmentation:

By Type

• Monoclonal Antibodies
• Cytokines & Immunomodulators
• Cancer Vaccines
• Checkpoint Inhibitors

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Head and Neck Cancer
• Others

By End User

• Hospitals
• Cancer Research Centers
• Clinics

By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

KEY MARKET PLAYERS

The report also focuses on the leading players in the cancer immunotherapy market, providing information such as company profiles, product and specification, capacity, production, price, revenue and contact information. The report also discloses information about the strategies adopted by the players which they use to sustain and grow in the market. The major players mentioned in the report include Novartis, AstraZeneca, Bristol-Myers Squibb, Amgen, F. Hoffman La-Roche, Eli Lilly and Company, Merck & Co., Inc., Janssen Global Services, LLC, Bayer AG, and Pfizer.

KEY TAKEAWAYS FROM THE CANCER IMMUNOTHERAPY MARKET REPORT

• The report provides a comprehensive analysis of the cancer immunotherapy market, incorporating the market size, market share analysis, market classification, market comparison analysis, market status and forecast analysis, development trends in the market, and company profiles.
• The report includes the current market trends and estimations for the period, 2018-2025 to identify the prevailing market opportunities across the various regions where the market has been analyzed.
• The study includes the top investment pockets to assist stakeholders in identifying the cash cows of the industry.
• The report includes an analysis of the factors that drive and impede the growth of the market.
• Key manufacturers of the cancer immunotherapy market are profiled in the report along with the recent developments to understand the competitive landscape.
• A comprehensive analysis of the market helps in assessing the growth strategies adopted by the key players over the past few years.

Contents

1. EXECUTIVE SUMMARY

1.1. Key findings
1.2. Market attractiveness and trend analysis
1.3. Competitive landscape and recent industry development analysis

2. INTRODUCTION

2.1. Report description
2.2. Scope and definitions
2.3. Research methodology

3. MARKET LANDSCAPE

3.1. Growth drivers
  3.1.1. Impact analysis
3.2. Restrains and challenges
  3.2.1. Impact analysis
3.3. Porters analysis
  3.3.1. Bargaining power of buyers
  3.3.2. Bargaining power of suppliers
  3.3.3. Threat of substitutes
  3.3.4. Industry rivalry
  3.3.5. Threat of new entrants
3.4. Global cancer immunotherapy market shares analysis, 2014-2025
  3.4.1. Global cancer immunotherapy market share by type, 2014-2025
  3.4.2. Global cancer immunotherapy market share by application, 2014-2025
  3.4.3. Global cancer immunotherapy market share by geography, 2014-2025

4. GLOBAL CANCER IMMUNOTHERAPY MARKET BY TYPE

4.1. Monoclonal antibodies
  4.1.1. Historical market size by region, 2014-2016
  4.1.2. Market forecast by region, 2017-2025
4.2. Immunomodulators
  4.2.1. Historical market size by region, 2014-2016
  4.2.2. Market forecast by region, 2017-2025
4.3. Cancer vaccines
  4.3.1. Historical market size by region, 2014-2016
  4.3.2. Market forecast by region, 2017-2025
4.4. Checkpoint inhibitors
  4.4.1. Historical market size by region, 2014-2016
  4.4.2. Market forecast by region, 2017-2025

5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY APPLICATION

5.1. Breast cancer
  5.1.1. Historical market size by region, 2014-2016
  5.1.2. Market forecast by region, 2017-2025
5.2. Lung cancer
  5.2.1. Historical market size by region, 2014-2016
  5.2.2. Market forecast by region, 2017-2025
5.3. Colorectal cancer
  5.3.1. Historical market size by region, 2014-2016
  5.3.2. Market forecast by region, 2017-2025
5.4. Prostate cancer
  5.4.1. Historical market size by region, 2014-2016
  5.4.2. Market forecast by region, 2017-2025
5.5. Melanoma
  5.5.1. Historical market size by region, 2014-2016
  5.5.2. Market forecast by region, 2017-2025
5.6. Head and neck cancer
  5.6.1. Historical market size by region, 2014-2016
  5.6.2. Market forecast by region, 2017-2025
5.7. Others
  5.7.1. Historical market size by region, 2014-2016
  5.7.2. Market forecast by region, 2017-2025

6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GEOGRAPHY

6.1. North America
  6.1.1. U.S.
    6.1.1.1. Historical market size, 2014-2016
    6.1.1.2. Market forecast, 2017-2025
  6.1.2. Canada
    6.1.2.1. Historical market size, 2014-2016
    6.1.2.2. Market forecast, 2017-2025
  6.1.3. Mexico
    6.1.3.1. Historical market size, 2014-2016
    6.1.3.2. Market forecast, 2017-2025
6.2. Europe
  6.2.1. UK
    6.2.1.1. Historical market size, 2014-2016
    6.2.1.2. Market forecast, 2017-2025
  6.2.2. Germany
    6.2.2.1. Historical market size, 2014-2016
    6.2.2.2. Market forecast, 2017-2025
  6.2.3. France
    6.2.3.1. Historical market size, 2014-2016
    6.2.3.2. Market forecast, 2017-2025
  6.2.4. Spain
    6.2.4.1. Historical market size, 2014-2016
    6.2.4.2. Market forecast, 2017-2025
  6.2.5. Italy
    6.2.5.1. Historical market size, 2014-2016
    6.2.5.2. Market forecast, 2017-2025
  6.2.6. Rest of Europe
    6.2.6.1. Historical market size, 2014-2016
    6.2.6.2. Market forecast, 2017-2025
6.3. Asia-Pacific
  6.3.1. China
    6.3.1.1. Historical market size, 2014-2016
    6.3.1.2. Market forecast, 2017-2025
  6.3.2. Japan
    6.3.2.1. Historical market size, 2014-2016
    6.3.2.2. Market forecast, 2017-2025
  6.3.3. India
    6.3.3.1. Historical market size, 2014-2016
    6.3.3.2. Market forecast, 2017-2025
  6.3.4. Australia
    6.3.4.1. Historical market size, 2014-2016
    6.3.4.2. Market forecast, 2017-2025
  6.3.5. South Korea
    6.3.5.1. Historical market size, 2014-2016
    6.3.5.2. Market forecast, 2017-2025
  6.3.6. Rest of Asia-Pacific
    6.3.6.1. Historical market size, 2014-2016
    6.3.6.2. Market forecast, 2017-2025
6.4. LAMEA
  6.4.1. Brazil
    6.4.1.1. Historical market size, 2014-2016
    6.4.1.2. Market forecast, 2017-2025
  6.4.2. Saudi Arabia
    6.4.2.1. Historical market size, 2014-2016
    6.4.2.2. Market forecast, 2017-2025
  6.4.3. South Africa
    6.4.3.1. Historical market size, 2014-2016
    6.4.3.2. Market forecast, 2017-2025
  6.4.4. Rest of LAMEA
    6.4.4.1. Historical market size, 2014-2016
    6.4.4.2. Market forecast, 2017-2025

7. COMPANY PROFILES

7.1. Amgen
  7.1.1. Overview
  7.1.2. Financials and business segments
  7.1.3. Recent developments
7.2. Astrazeneca
  7.2.1. Overview
  7.2.2. Financials and business segments
  7.2.3. Recent developments
7.3. Bayer ag
  7.3.1. Overview
  7.3.2. Financials and business segments
  7.3.3. Recent developments
7.4. F. Hoffman la-roche
  7.4.1. overview
  7.4.2. Financials and business segments
  7.4.3. Recent developments
7.5. Bristol-myers squibb
  7.5.1. Overview
  7.5.2. Financials and business segments
  7.5.3. Recent developments
7.6. Janssen global services, llc
  7.6.1. overview
  7.6.2. Financials and business segments
  7.6.3. Recent developments
7.7. Eli lilly and company
  7.7.1. Overview
  7.7.2. Financials and business segments
  7.7.3. Recent developments
7.8. Merck & co., inc.
  7.8.1. overview
  7.8.2. Financials and business segments
  7.8.3. Recent developments
7.9. Novartis
  7.9.1. Overview
  7.9.2. Financials and business segments
  7.9.3. Recent developments
7.10. Pfizer inc.
  7.10.1. Overview
  7.10.2. Financials and business segments
  7.10.3. Recent developments

List Of Tables

LIST OF TABLES

Table 1.Cancer Immunotherapy Market Share, by Type, 2014-2025
Table 2.Cancer Immunotherapy Market Share, by Application, 2014-2025
Table 3.Cancer Immunotherapy Market Share, by Region, 2014-2025
Table 4.Cancer Immunotherapy Market Value for Monoclonal Antibodies, by Region, 2017-2025, $million
Table 5.Cancer Immunotherapy Market Value for Immunomodulators, by Region, 2017-2025, $million
Table 6.Cancer Immunotherapy Market Value for Cancer Vaccines, by Region, 2017-2025, $million
Table 7.Cancer Immunotherapy Market Value for Checkpoint Inhibitors, by Region, 2017-2025, $million
Table 8.Cancer Immunotherapy Market Value for Breast Cancer, by Region, 2017-2025, $million
Table 9.Cancer Immunotherapy Market Value for Lung Cancer, by Region, 2017-2025, $million
Table 10.Cancer Immunotherapy Market Value for Colorectal Cancer, by Region, 2017-2025, $million
Table 11.Cancer Immunotherapy Market Value for Prostate Cancer, by Region, 2017-2025, $million
Table 12.Cancer Immunotherapy Market Value for Melanoma, by Region, 2017-2025, $million
Table 13.Cancer Immunotherapy Market Value for Head and Neck Cancer, by Region, 2017-2025, $million
Table 14.Cancer Immunotherapy Market Value for Others, by Region, 2017-2025, $million
Table 15.Cancer Immunotherapy Market Value for North America, by Country, 2014-2025, $million
Table 16.Cancer Immunotherapy Market Value for North America, by Type, 2014-2025, $million
Table 17.Cancer Immunotherapy Market Value for North America, by Application, 2014-2025, $million
Table 18.Cancer Immunotherapy Market Value for Europe, by Country, 2014-2025, $million
Table 19.Cancer Immunotherapy Market Value for Europe, by Type, 2014-2025, $million
Table 20.Cancer Immunotherapy Market Value for Europe, by Application, 2014-2025, $million
Table 21.Cancer Immunotherapy Market Value for Asia-Pacific, by Country, 2014-2025, $million
Table 22.Cancer Immunotherapy Market Value for Asia-Pacific, by Type, 2014-2025, $million
Table 23.Cancer Immunotherapy Market Value for Asia-Pacific, by Application, 2014-2025, $million
Table 24.Cancer Immunotherapy Market Value for LAMEA, by Country, 2014-2025, $million
Table 25.Cancer Immunotherapy Market Value for LAMEA, by Type, 2014-2025, $million
Table 26.Cancer Immunotherapy Market Value for LAMEA, by Application, 2014-2025, $million
Table 27. Amgen - Company Snapshot
Table 28. AstraZeneca - Company Snapshot
Table 29. Bayer AG - Company Snapshot
Table 30. F. Hoffman La-Roche - Company Snapshot
Table 31. Janssen Global Services, LLC - Company Snapshot
Table 32. Eli Lilly and Company - Company Snapshot
Table 33. Merck & Co., Inc. - Company Snapshot
Table 34. Novartis - Company Snapshot
Table 35. Pfizer - Company Snapshot
Table 36. Bristol-Myers Squibb - Company Snapshot

List Of Figures

LIST OF FIGURES

Figure 1.Cancer Immunotherapy: Monoclonal Antibodies Market Value, 2014-2016, $million
Figure 2.Cancer Immunotherapy: Immunomodulators Market Value, 2014-2016, $million
Figure 3.Cancer Immunotherapy: Cancer Vaccines Market Value, 2014-2016, $million
Figure 4.Cancer Immunotherapy: Checkpoint Inhibitors Market Value, 2014-2016, $million
Figure 5.Cancer Immunotherapy: Breast Cancer Market Value, 2014-2016, $million
Figure 6.Cancer Immunotherapy: Lung Cancer Market Value, 2014-2016, $million
Figure 7.Cancer Immunotherapy: Colorectal Cancer Market Value, 2014-2016, $million
Figure 8.Cancer Immunotherapy: Prostate Cancer Market Value, 2014-2016, $million
Figure 9.Cancer Immunotherapy: Melanoma Market Value, 2014-2016, $million
Figure 10.Cancer Immunotherapy: Head and Neck Cancer Market Value, 2014-2016, $million
Figure 11.Cancer Immunotherapy: Others Market Value, 2014-2016, $million
Figure 12.Cancer Immunotherapy: U.S. Market Value, 2014-2016, $million
Figure 13.Cancer Immunotherapy: U.S. Market Value, 2017-2025, $million
Figure 14.Cancer Immunotherapy: Canada Market Value, 2014-2016, $million
Figure 15.Cancer Immunotherapy: Canada Market Value, 2017-2025, $million
Figure 16.Cancer Immunotherapy: Mexico Market Value, 2014-2016, $million
Figure 17.Cancer Immunotherapy: Mexico Market Value, 2017-2025, $million
Figure 18.Cancer Immunotherapy: UK Market Value, 2014-2016, $million
Figure 19.Cancer Immunotherapy: UK Market Value, 2017-2025, $million
Figure 20.Cancer Immunotherapy: Germany Market Value, 2014-2016, $million
Figure 21.Cancer Immunotherapy: Germany Market Value, 2017-2025, $million
Figure 22.Cancer Immunotherapy: France Market Value, 2014-2016, $million
Figure 23.Cancer Immunotherapy: France Market Value, 2017-2025, $million
Figure 24.Cancer Immunotherapy: Spain Market Value, 2014-2016, $million
Figure 25.Cancer Immunotherapy: Spain Market Value, 2017-2025, $million
Figure 26.Cancer Immunotherapy: Italy Market Value, 2014-2016, $million
Figure 27.Cancer Immunotherapy: Italy Market Value, 2017-2025, $million
Figure 28.Cancer Immunotherapy: Rest of Europe Market Value, 2014-2016, $million
Figure 29.Cancer Immunotherapy: Rest of Europe Market Value, 2017-2025, $million
Figure 30.Cancer Immunotherapy: China Market Value, 2014-2016, $million
Figure 31.Cancer Immunotherapy: China Market Value, 2017-2025, $million
Figure 32.Cancer Immunotherapy: Japan Market Value, 2014-2016, $million
Figure 33.Cancer Immunotherapy: Japan Market Value, 2017-2025, $million
Figure 34.Cancer Immunotherapy: India Market Value, 2014-2016, $million
Figure 35.Cancer Immunotherapy: India Market Value, 2017-2025, $million
Figure 36.Cancer Immunotherapy: Australia Market Value, 2014-2016, $million
Figure 37.Cancer Immunotherapy: Australia Market Value, 2017-2025, $million
Figure 38.Cancer Immunotherapy: South Korea Market Value, 2014-2016, $million
Figure 39.Cancer Immunotherapy: South Korea Market Value, 2017-2025, $million
Figure 40.Cancer Immunotherapy: Rest of Asia-Pacific Market Value, 2014-2016, $million
Figure 41.Cancer Immunotherapy: Rest of Asia-Pacific Market Value, 2017-2025, $million
Figure 42.Cancer Immunotherapy: Brazil Market Value, 2014-2016, $million
Figure 43.Cancer Immunotherapy: Brazil Market Value, 2017-2025, $million
Figure 44.Cancer Immunotherapy: Saudi Arabia Market Value, 2014-2016, $million
Figure 45.Cancer Immunotherapy: Saudi Arabia Market Value, 2017-2025, $million
Figure 46.Cancer Immunotherapy: South Africa Market Value, 2014-2016, $million
Figure 47.Cancer Immunotherapy: South Africa Market Value, 2017-2025, $million
Figure 48.Cancer Immunotherapy: Rest of LAMEA Market Value, 2014-2016, $million
Figure 49.Cancer Immunotherapy: Rest of LAMEA Market Value, 2017-2025, $mill